XOMA (XOMA) Competitors $25.00 -0.09 (-0.36%) As of 02:15 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XOMA vs. NVAX, OPK, GERN, RGLS, ZBIO, MYGN, RIGL, EBS, VSTM, and VNDAShould you be buying XOMA stock or one of its competitors? The main competitors of XOMA include Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), Verastem (VSTM), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. XOMA vs. Its Competitors Novavax OPKO Health Geron Regulus Therapeutics Zenas Biopharma Myriad Genetics Rigel Pharmaceuticals Emergent BioSolutions Verastem Vanda Pharmaceuticals XOMA (NASDAQ:XOMA) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations. Does the MarketBeat Community believe in XOMA or NVAX? Novavax received 408 more outperform votes than XOMA when rated by MarketBeat users. Likewise, 74.02% of users gave Novavax an outperform vote while only 65.68% of users gave XOMA an outperform vote. CompanyUnderperformOutperformXOMAOutperform Votes44465.68% Underperform Votes23234.32% NovavaxOutperform Votes85274.02% Underperform Votes29925.98% Does the media prefer XOMA or NVAX? In the previous week, Novavax had 14 more articles in the media than XOMA. MarketBeat recorded 15 mentions for Novavax and 1 mentions for XOMA. XOMA's average media sentiment score of 1.87 beat Novavax's score of 0.90 indicating that XOMA is being referred to more favorably in the media. Company Overall Sentiment XOMA Very Positive Novavax Positive Which has better earnings and valuation, XOMA or NVAX? XOMA has higher earnings, but lower revenue than Novavax. XOMA is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA$13.05M22.93-$40.83M-$1.15-21.74Novavax$1.21B0.97-$545.06M$2.652.74 Do analysts rate XOMA or NVAX? XOMA currently has a consensus target price of $69.50, suggesting a potential upside of 178.00%. Novavax has a consensus target price of $19.00, suggesting a potential upside of 162.07%. Given XOMA's stronger consensus rating and higher possible upside, research analysts clearly believe XOMA is more favorable than Novavax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Novavax 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Is XOMA or NVAX more profitable? Novavax has a net margin of -32.18% compared to XOMA's net margin of -151.34%. Novavax's return on equity of 0.00% beat XOMA's return on equity.Company Net Margins Return on Equity Return on Assets XOMA-151.34% -24.95% -9.64% Novavax -32.18%N/A -17.05% Do insiders & institutionals believe in XOMA or NVAX? 95.9% of XOMA shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 9.1% of XOMA shares are held by insiders. Comparatively, 1.0% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, XOMA or NVAX? XOMA has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.81, meaning that its share price is 181% more volatile than the S&P 500. SummaryNovavax beats XOMA on 10 of the 18 factors compared between the two stocks. Get XOMA News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$299.18M$6.93B$5.60B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-7.188.8727.2520.01Price / Sales22.93263.25412.71157.94Price / CashN/A65.8538.2534.64Price / Book3.246.617.124.70Net Income-$40.83M$144.20M$3.24B$248.05M7 Day PerformanceN/A3.88%2.75%2.62%1 Month Performance0.85%11.26%9.00%6.32%1 Year Performance-0.04%3.96%31.41%13.78% XOMA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA4.2381 of 5 stars$25.00-0.4%$69.50+178.0%+4.5%$299.18M$13.05M-7.1810Positive NewsNVAXNovavax3.891 of 5 stars$7.41-0.5%$19.00+156.4%-57.6%$1.20B$1.21B-3.281,990Trending NewsOPKOPKO Health4.493 of 5 stars$1.38+1.5%$2.75+99.3%+2.3%$1.09B$689.41M-7.264,200News CoverageGERNGeron3.1579 of 5 stars$1.62+1.3%$5.06+212.5%-69.7%$1.03B$116.29M-5.0670Gap DownRGLSRegulus Therapeutics1.7549 of 5 stars$8.30+1.0%$8.50+2.4%+237.5%$574.64MN/A-7.7630Positive NewsZBIOZenas Biopharma1.3256 of 5 stars$11.92+7.2%$36.67+207.6%N/A$498.66M$15M-3.36N/ATrending NewsMYGNMyriad Genetics4.2007 of 5 stars$5.19+2.0%$14.38+177.2%-76.9%$478.40M$831.30M-3.992,600Positive NewsRIGLRigel Pharmaceuticals3.2848 of 5 stars$21.85+1.7%$36.40+66.6%+107.7%$390.50M$203.08M156.08160Positive NewsAnalyst RevisionEBSEmergent BioSolutions4.366 of 5 stars$6.50-2.0%$14.33+120.7%+3.0%$352.54M$930.30M-1.582,420VSTMVerastem3.2163 of 5 stars$6.11-4.8%$13.63+123.0%+72.0%$335.74M$10M-1.9250Positive NewsVNDAVanda Pharmaceuticals4.6957 of 5 stars$4.59-0.4%$16.50+259.5%-23.5%$270.51M$201.35M-14.34290Positive NewsAnalyst Revision Related Companies and Tools Related Companies Novavax Alternatives OPKO Health Alternatives Geron Alternatives Regulus Therapeutics Alternatives Zenas Biopharma Alternatives Myriad Genetics Alternatives Rigel Pharmaceuticals Alternatives Emergent BioSolutions Alternatives Verastem Alternatives Vanda Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XOMA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
